Baylor Genetics

baylorgenetics.com

Baylor Genetics is a joint venture of Miraca Holdings, Inc. and Baylor College of Medicine, including the #1 NIH-funded Department of Molecular and Human Genetics. A pioneer of precision medicine for nearly 40 years, Baylor Genetics now offers a full spectrum of clinically relevant genetic testing, access to world-renowned experts, and the confidence to provide patients with the best care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

ANUVA ANNOUNCES SERIES A CLOSURE AND ENTERS INTO A STRATEGIC PARTNERSHIP WITH HELIX

Anuva and Helix | August 30, 2022

news image

Anuva enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva will be generating new knowledge on health and disease, directly applicable to treatments, on diverse under-represented populations to advance drug discovery through the identification of novel targ...

Read More

CELL AND GENE THERAPY, MEDTECH

NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS

Nkarta, Inc. | December 06, 2022

news image

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Read More

MEDICAL

ABC OPENS COMMERCIAL MEL BIOSURFACTANT PRODUCTION IN IRVINE, CA

ABC | May 19, 2022

news image

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...

Read More

MEDTECH

LYSANDO AG AND AMICOGEN INC. SIGN GENERAL DEVELOPMENT AGREEMENT

Lysando AG and Amicogen Inc. | October 19, 2022

news image

Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea. In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement. " Read More

news image

CELL AND GENE THERAPY

ANUVA ANNOUNCES SERIES A CLOSURE AND ENTERS INTO A STRATEGIC PARTNERSHIP WITH HELIX

Anuva and Helix | August 30, 2022

Anuva enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva will be generating new knowledge on health and disease, directly applicable to treatments, on diverse under-represented populations to advance drug discovery through the identification of novel targ...

Read More
news image

CELL AND GENE THERAPY, MEDTECH

NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS

Nkarta, Inc. | December 06, 2022

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Read More
news image

MEDICAL

ABC OPENS COMMERCIAL MEL BIOSURFACTANT PRODUCTION IN IRVINE, CA

ABC | May 19, 2022

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...

Read More
news image

MEDTECH

LYSANDO AG AND AMICOGEN INC. SIGN GENERAL DEVELOPMENT AGREEMENT

Lysando AG and Amicogen Inc. | October 19, 2022

Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea. In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement. " Read More